Radnostix

INIS

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.07

-0.00 (-0.43%)

Market Cap

$37.0M

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+10.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 477.7M (2021) → 526.8M (2025)

I don't have reliable information about a company called **Radnostix, Inc.** with the ticker **INIS**. This company does not appear in my training data, and I cannot find a confident match to describe its products, customers, or operations accurately.

Rather than guess and risk publishing inaccurate information on a research platform, I'd recommend:

- **Verifying the ticker and company name** — INIS may be associated with a different company name, or the company may be very small or recently renamed. - **Checking SEC EDGAR** (edgar.sec.gov) for the company's most recent 10-K or 10-Q filing, which will clearly describe the business. - **Using the company's investor relations page** for an accurate business description.

Once you have the correct company details, I'm happy to write the two-paragraph description using the format above.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-25.7% YoY

YoY Growth Rate

Revenue declining

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$435.8B/ year

↑ Rising (+71362860% vs prior year)

>1,000% of revenue

185254.1x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

79.8%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$1.7T cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Heavy R&D investment

Radnostix is putting 3334574% of revenue into R&D and that number is rising. That's 185254.1x the sector average. And they're generating enough cash to self-fund it.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

94.9%

Premium pricing power — 94.9% gross margin

Operating Margin

-19.8%

Losing money on operations — -19.8%

ROCE

-10.2%

Weak — -10.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-6.0%

Shrinking sales (-6.0% YoY)

EPS YoY

-1723631000.0%

Earnings shrinking (-1723631000.0% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

0.7%

Thin free cash flow (0.7%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.52

Conservative — low debt load (0.52)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial